Is there any relationship between the exposure to mycophenolic acid and the clinical status in children with lupus?

por Jurado, C, Bader-Meunier, B, Ranchin, B, Decramer, S, Fischbac, M, Bérard, E, Saint-Marcoux, F
Publicado 2011

PReS-FINAL-2175: Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring

por Woillard, JB, Bader-Meunier, B, Salomon, R, Ranchin, B, Decramer, S, Fischbach, M, Berard, E, Saint-Marcoux, F
Publicado 2013

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.

por Warzocha, K., Bienvenu, J., Ribeiro, P., Moullet, I., Dumontet, C., Neidhardt-Berard, E. M., Coiffier, B., Salles, G.
Publicado 1998

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

por Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J.-P., Guimbaud, R., Meyer, N., Mazieres, J., Alric, L.
Publicado 2019

Evaluation of bladder stimulation as a non-invasive technique for urine collection to diagnose urinary tract infection in infants under 6 months: a randomized multicenter study (“E...

por Demonchy, D., Ciais, C., Fontas, E., Berard, E., Bréaud, J., Rohrlich, P. S., Dubos, F., Fortier, C., Desmontils, J., Hérisse, A. L., Donzeau, D., Haas, H., Tran, A.
Publicado 2019

Pharmacological targeting of NF-κB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells

por Lagadec, P, Griessinger, E, Nawrot, M P, Fenouille, N, Colosetti, P, Imbert, V, Mari, M, Hofman, P, Czerucka, D, Rousseau, D, Berard, E, Dreano, M, Peyron, J F
Publicado 2008

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study

por Mouriaux, F, Servois, V, Parienti, J J, Lesimple, T, Thyss, A, Dutriaux, C, Neidhart-Berard, E M, Penel, N, Delcambre, C, Peyro Saint Paul, L, Pham, A D, Heutte, N, Piperno-Neumann, S, Joly, F
Publicado 2016

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

por Heudel, P., Chabaud, S., Perol, D., Flechon, A., Fayette, J., Combemale, P., Tredan, O., Desseigne, F., de la Fouchardiere, C., Boyle, H., Perol, M., Bachelot, T., Cassier, P., Avrillon, V., Terret, C., Michallet, A.-S., Neidhardt-Berard, E.-M., Nicolas-Virelizier, E., Dufresne, A., Belhabri, A., Brahmi, M., Lebras, L., Nicolini, F., Sarabi, M., Rey, P., Bonneville-Levard, A., Rochefort, P., Provensal, A.-M., Eberst, L., Assaad, S., Swalduz, A., Saintigny, P., Toussaint, P., Guillermin, Y., Castets, M., Coutzac, C., Meeus, P., Dupré, A., Durand, T., Crochet, H., Fervers, B., Gomez, F., Rivoire, M., Gregoire, V., Claude, L., Chassagne-Clement, C., Pilleul, F., Mognetti, T., Russias, B., Soubirou, J.-L., Lasset, C., Chvetzoff, G., Mehlen, P., Beaupère, S., Zrounba, P., Ray-Coquard, I., Blay, J.-Y.
Publicado 2021